NCT00912080Unknown不适用
Utilisation of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer: A Prospective Cohort Study.
Institut Paoli-Calmettes4 个研究点 分布在 1 个国家目标入组 375 人开始时间: 2007年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 375
- 试验地点
- 4
- 主要终点
- Estimation of metastasis free survival at 5 years of the patients who had a good genomic signature. The metastasis free survival is defined by the time between the histological diagnosis of the breast cancer and the apparition of the first metastasis.
研究概览
简要总结
Method: This multicentric prospective cohort is composed of patients with no metastatic breast cancer selected by tumor's genomic analysis and treated by chemotherapy with Anthracycline without Taxanes (6 cycles of FEC 100).
The patient can be included before or after the surgery and a written consent must be signed for the proteomic and genomic analysis of the tumor.
Patients who have a "good signature" for the genomic analysis will receive the standard chemotherapy.
Primary objective:
- To compare metastasis free survival at 5 years in a cohort of patients with no metastatic breast cancer, who are selected by their genomic profile of the tumor and received a standard chemotherapy containing Anthracycline, with result of retrospectives studies.
Secondary Objectives:
- Overall survival.
- Creation of a circuit (transport-extraction-genomic analysis-result) which allows the beginning of the chemotherapy within 6 weeks following the primary surgery.
- Histological and seric proteomic exploratory studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged between 18 and 70
- •Patient with life condition < 2 (WHO scale)
- •One-sided breast adenocarcinoma with a histological evidence (all type)
- •Clinical presentation which allowed a complete surgery with healthy limits
- •Absence of metastasis detectable at clinical examination or radiology
- •Histological evidence for homolateral axillary ganglionic invasion, whatever is the number of node invaded (N > 1)
- •The beginning of the chemotherapy within 6 weeks following the primary surgery
排除标准
- •All metastatic affect
- •Tumor classed >= T4a: cutaneous invasion, deep adherence, inflammatory breast
- •All chemotherapy, hormonotherapy or radiotherapy before surgery
- •Tumoral residue not removed
- •Any suspect clinic or radiologic lesion, in the contralateral breast, which is not controlled
- •History of invasive neoplasm, mammary or other (except in situ carcinoma of cervix uteri and epithelioma)
结局指标
主要结局
Estimation of metastasis free survival at 5 years of the patients who had a good genomic signature. The metastasis free survival is defined by the time between the histological diagnosis of the breast cancer and the apparition of the first metastasis.
时间窗: 5 years
次要结局
- Time between collection for the genomic signature study and the beginning of the chemotherapy.(6 weeks)
- Seric and histological proteomic exploratory studies with SELDI-TOF MS to: search correlation with histo-clinical or/and molecular parameter and to identify one or few proteic signature with a prognosis value.(6 weeks)
- Overall survival.(5 years)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast CancerMetastatic Breast CancerNCT03195192Side-Out Foundation28
撤回
不适用
Molecular Triaging of Newly Diagnosed Breast CancerBreast CancerNCT01159236M.D. Anderson Cancer Center
尚未招募
不适用
Gene profiling study for the patients with breast cancerBreast cancerJPRN-UMIN000021269Toranomon Hospital750
Unknown
不适用
Genetic Characteristics of Metastatic Breast Cancer PatientsMetastatic Breast CancerNCT04258735Samsung Medical Center300
Unknown
不适用
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot StudyBreast TumorNCT01247467National University Hospital, Singapore10